首页> 外文OA文献 >The Lifetime Economic Burden of Inaccurate HER2 Testing: Estimating the Costs of False-Positive and False-Negative HER2 Test Results in US Patients with Early-Stage Breast Cancer

【2h】

The Lifetime Economic Burden of Inaccurate HER2 Testing: Estimating the Costs of False-Positive and False-Negative HER2 Test Results in US Patients with Early-Stage Breast Cancer

机译：不准确的HER2测试的终生经济负担：估算美国早期乳腺癌患者中错误阳性和错误阴性HER2测试结果的成本

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
引文网络
相似文献
相关主题

著录项

作者
Garrison Louis P.; Babigumira Joseph B.; Masaquel Anthony; Wang Bruce C.M.; Lalla Deepa; Brammer Melissa;
展开▼
作者单位

展开▼
年度 2015
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. The Lifetime Economic Burden of Inaccurate HER2 Testing: Estimating the Costs of False-Positive and False-Negative HER2 Test Results in US Patients with Early-Stage Breast Cancer [J] . Garrison Louis P. Jr., Babigumira Joseph B., Masaquel Anthony, Value in health: the journal of the International Society for Pharmacoeconomics and Outcomes Research . 2015,第4期

机译：不准确的HER2测试的终生经济负担：估算美国早期乳腺癌患者中假阳性和假阴性HER2测试结果的成本
2. Amplification of the HER2 gene in breast cancers testing 2+ weak positive by HercepTest immunohistochemistry: false-positive or false-negative immunohistochemistry? [J] . Ciara Barrett, Hilary Magee, Denise OToole, Journal of Clinical Pathology . 2007,第6期

机译：通过HercepTest免疫组织化学检测2 +弱阳性的乳腺癌中HER2基因的扩增：假阳性或假阴性免疫组织化学？
3. Assessing the potential cost-effectiveness of retesting IHC0, IHC1+, or FISH-negative early stage breast cancer patients for HER2 status [J] . GarrisonJr.L.P., LallaD., BrammerM., Cancer: A Journal of the American Cancer Society . 2013,第17期

机译：评估重新测试IHC0，IHC1 +或FISH阴性的早期乳腺癌患者的HER2状态的潜在成本效益
4. Risk classification for breast cancer diagnosis using HER2 testing [C] . Pınar Ece Aktan, Gökhan Hatipoğlu, Nafiz Arica 2016 24th Signal Processing and Communication Application Conference . 2016

机译：使用HER2测试进行乳腺癌诊断的风险分类
5. Analysis of HER2 testing in breast cancer: Disparities, cost-effectiveness, and patterns of care. [D] . Ashok, Mahima. 2009

机译：乳腺癌HER2检测分析：差异，成本效益和护理方式。
6. Clinical Practice Patterns and Cost-Effectiveness of HER2 Testing Strategies in Breast Cancer Patients [O] . Kathryn A. Phillips, Deborah A. Marshall, Jennifer S. Haas, -1

机译：乳腺癌患者中HER2测试策略的临床实践模式和成本效益
7. Assessing the potential cost-effectiveness of retesting IHC0, IHC1+, or FISH-negative early stage breast cancer patients for HER2 status [O] . Louis P. Garrison, Deepa Lalla, Melissa Brammer, 2013

机译：评估重试IHC0，IHC1 +或鱼类阴性早期乳腺癌患者为HER2地位的潜在成本效益
8. HER2 Testing to Manage Patients With Breast Cancer or Other Solid Tumors. Evidence Report/Technology Assessment 172 [R] . Seidenfeld, J., Samson, F. J., Rotherberg, B. M., 2008

机译：HER2测试管理患有乳腺癌或其他实体瘤的患者。证据报告/技术评估172

The Lifetime Economic Burden of Inaccurate HER2 Testing: Estimating the Costs of False-Positive and False-Negative HER2 Test Results in US Patients with Early-Stage Breast Cancer

著录项

引文网络

相似文献

相关主题

期刊订阅